Upstream Bio reports preliminary cash of $341.5M; Phase 2 VALIANT top-line data released

Upstream Bio, Inc.

Preliminary unaudited cash, cash equivalents and short-term investments of $341.5M as of Dec 31, 2025.
Top-line results from Phase 2 VALIANT trial of verekitug in severe asthma presented in webcast; details in investor presentation.
Year-end 2025 financial close not yet completed; full results to be included in Form 10-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.